|
|
 | | | |
- close
- close
- close
- close
QUOTE AND NEWS
Marketwire
May 24
Comment
BEDFORD, MA -- (Marketwire) -- 05/24/12 -- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced the company will participate in the following upcoming
StreetInsider.com
May 9
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Insulet+Corporation+%28PODD%29+Misses+Posts+Q1+Loss+of+%240.31/7421016.html for the full story.
Marketwire
May 9
Comment
BEDFORD, MA -- (Marketwire) -- 05/09/12 -- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced financial results for the first quarter ended March 31, 2012.
Marketwire
Apr 30
Comment
BEDFORD, MA -- (Marketwire) -- 04/30/12 -- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced the Company will participate in the 11th Annual JMP Securities
Marketwire
Apr 26
Comment
BEDFORD, MA -- (Marketwire) -- 04/26/12 -- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, announced plans to release its financial results for the first quarter 2012 on
Marketwire
Apr 11
Comment
BEDFORD, MA -- (Marketwire) -- 04/11/12 -- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced the expansion and extension of its distribution partnership
Benzinga
Feb 15
Comment
Insulet Corporation (NASDAQ: PODD) today announced it has signed a worldwide agreement with LifeScan, Inc. to integrate LifeScan's OneTouch® blood glucose monitoring technology into the OmniPod Personal Diabetes Manager.
Under the terms of...
Benzinga
Feb 13
Comment
Feltl & Company reiterates its Buy rating on Insulet (NASDAQ: PODD) and increased its price target to $22.10 from $18.60 on better than expected guidance for revenues in 2012.
Feltl & Company notes, "Insulet reported EPS of ($0.30) versus our...
Benzinga
Feb 10
Comment
Jefferies maintains its Buy rating on Insulet (NASDAQ: PODD) and raises its price target to $24 from $21 a share as the company's next generation of pods awaits FDA approval.
Jefferies says, "Insulet closed out 2011 with 4Q sales of $47.2mn,...
Benzinga
Feb 10
Comment
Wunderlich Securities maintains its Buy rating and $22 target price on Insulet Corporation (NASDAQ: PODD) as the company's fourth quarter results beat estimates slightly.
Wunderlich Securities says, "Insulet Corp. (PODD) reported Q4 revenues...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
TOP CONTRIBUTORS
Insulet (PODD) is competing against Mini Med, a division of Medtronic, for the insulin delivery system segment. The product has a needle which is inserted until an audible sound is heard, then the needle withdraws leaving behind a tethlon tube. Insuline is dripped from the pod into the body via the tube. When the pod is low on the solution, more is added. This avoids the nasty needle sticks many diabetics loath.
The pod can be worn many places on the body and has no major tubes of complicated computer readouts, vs. the typical insulin pump.
Often a physician asks the patient to try wearing the pod while it drips saline. Uptake is high afterwards as the pod is so comfortable.
Per the CEO, Duane Desisto, they may have a pump company burried in a pod company. Meaning that other drugs may be delivered via the pod.
References
| |||||||
